Testosterone Lawsuit Information Center
Testosterone lawsuit claims are now being evaluated by our law firm on behalf of men who may have suffered a heart attack or stroke due to their use of AndroGel or another prescription testosterone treatment. Millions of men in the U.S. have used AndroGel and similar products for low testosterone, or “Low T.” But recently, these medications have come under scrutiny, following publication of studies which suggested a link between Low T therapy and an increased risk of serious cardiovascular events. The aggressive marketing methods used by pharmaceutical companies to drive sales of testosterone therapies have also raised questions, as the medications are often prescribed to men with normal levels of the hormone.
Financial compensation via a testosterone treatment lawsuit may be available to victims of heart attacks or strokes potentially associated with the use of a prescription-brand testosterone gel, patch, pellet or injectable. The attorneys at Bernstein Liebhard LLP are investigating lawsuits involving brand-name Low T drugs, including:
Alleged victims of heart attacks or strokes associated with AndroGel or other testosterone treatments can learn more about their possible legal rights by contacting our office for a free and no obligation legal review. Our legal staff will take the time to fully explain the process for filing an AndroGel lawsuit, and help you to determine whether or not you have a valid case. Don’t hesitate! To protect your legal rights, please call now to discuss your case with an experienced attorney today.
What is Testosterone Treatment?
Testosterone is a male hormone vital to the development of male growth and masculine characteristics. Low T therapy medications like AndroGel are approved for the treatment of abnormally-low testosterone levels, a condition known as hypogonadism. The U.S. Food & Drug Administration (FDA) has specifically stated that prescription therapies should only be used in men who suffer from low-t in conjunction with an associated medical problem, including certain genetic conditions, chemotherapy side effects, and problems with the hypothalamus or pituitary glands. However, according to a report published by The New York Times in February 2014, drug companies have heavily promoted these medications “as a cure-all for low energy, low libido, depression and other ills among middle-aged men.”
According to the Times, the use of Low T therapy among men over 40 quadrupled between 2001 and 2011. Today, one in 25 men over the age of 60 is undergoing prescription testosterone therapy. Some doctors even prescribe these drugs to men with normal levels, The New York Times said.
The methods used by the manufacturers of Low T therapies to drive sales of these medications have come under scrutiny in the past. In 1997, for example, the maker of AndroGel was taken to task by the FDA before the product even came on the market for promoting the drug for potential uses “such as the treatment of geriatric hypogonadism in elderly men.” Three years later, the FDA issued another warning letter that characterized as misleading marketing claims that “suggest that AndroGel is indicated for men with ‘age-associated’ hypogonadism.” The FDA letter emphasized that AndroGel was only approved for “primary” testicular problems and secondary problems like pituitary or hypothalamus disorders.
FDA Investigating AndroGel, Other Low T Therapies
In January 2014, the FDA announced it was reviewing the safety of AndroGel and other prescription testosterone products amid concerns that their use could increase the chances that certain men would experience heart attacks, strokes and other life-threatening cardiovascular events. One study, which appeared that same month in PLoS One reported that Low T therapy was associated with an increased risk of heart attack in men younger than 65 with a history of heart disease, and in older men without a history of heart problems. That study, which looked at 410,019 US men and 6,858 UK men who had initiated testosterone therapy, found that during the first 90 days of treatment, the risk of heart attack doubled in those two groups.
An earlier study that also caught the FDA’s attention involved 8,709 men with low testosterone who had undergone coronary angiography at the VA health system between 2005 and 2011, 1,233 of whom had undergone Low T therapy. The research, which appeared in the Journal of the American Medical Association in November 2013, suggested a 30 percent increased risk of stroke, heart attack, and death in the group that had been prescribed testosterone therapy.
In the Drug Safety Communication announcing its Low T safety review, the FDA emphasized that it has not concluded that use of testosterone treatments raise the risk of heart attack or stroke. However, the agency has cautioned doctors to consider their risks and benefits before prescribing any of the medications in this class.
Learn More about Filing a Testosterone Lawsuit
Victims of heart attacks or strokes related to the use of Low T therapy may be able to file an AndroGel lawsuit or other legal claim seeking compensation for their injury-related damages, including:
- Medical Bills
- Lost Wages
- Pain and Suffering
- Emotional Distress
- Permanent Disability
- Wrongful Death
If you suspect that you or a loved one were harmed by AndroGel or a similar product, it is important that you contact Bernstein Liebhard LLP today in order to ensure your legal rights are protected. Our attorneys have been fighting for the rights of injured consumers for over 20 years, and have recovered more than $3 billion for our clients. To learn how they can help you pursue a testosterone treatment lawsuit, please contact our office directly by calling.